Bloomfield M, Ashok A, Volkow N, Howes O
Nature. 2016; 539(7629):369-377.
PMID: 27853201
PMC: 5123717.
DOI: 10.1038/nature20153.
Nishibe Y, Matsuo Y, Yoshizaki T, Eigyo M, Shiomi T, Hirose K
Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(3):190-4.
PMID: 7155198
DOI: 10.1007/BF00505484.
Halbreich U, SACHAR E, Nathan R, Asnis G, Halpern F
Psychopharmacology (Berl). 1980; 72(1):61-5.
PMID: 6781007
DOI: 10.1007/BF00433807.
Roberts D, Vickers G
Psychopharmacology (Berl). 1984; 82(1-2):135-9.
PMID: 6141584
DOI: 10.1007/BF00426397.
Molander L, Borgstrom L
Psychopharmacology (Berl). 1983; 79(2-3):142-7.
PMID: 6133301
DOI: 10.1007/BF00427801.
Molecular pathology of schizophrenia: more than one disease process?.
Crow T
Br Med J. 1980; 280(6207):66-8.
PMID: 6101544
PMC: 1600263.
DOI: 10.1136/bmj.280.6207.66.
Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?.
Costall B, Naylor R
Psychopharmacologia. 1973; 32(2):161-70.
PMID: 4796282
DOI: 10.1007/BF00428687.
The role of dopamine in pilocarpine-induced catalepsy.
Ahtee L, Kaariainen I
Naunyn Schmiedebergs Arch Pharmacol. 1974; 284(1):25-38.
PMID: 4279348
DOI: 10.1007/BF00499970.
Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs.
Clement-Cormier Y, Kebabian J, Petzold G, Greengard P
Proc Natl Acad Sci U S A. 1974; 71(4):1113-7.
PMID: 4151517
PMC: 388173.
DOI: 10.1073/pnas.71.4.1113.
Effects of low and high doses of L-dopa on the tetrabenazine or alpha-methyltyrosine-induced suppression of behaviour in a successive discrimination task.
Ahlenius S
Psychopharmacologia. 1974; 39(3):199-212.
PMID: 4139729
DOI: 10.1007/BF00421027.
The effect of haloperidol on cocaine self-administration is augmented with repeated administrations.
Roberts D, Vickers G
Psychopharmacology (Berl). 1987; 93(4):526-8.
PMID: 3124187
DOI: 10.1007/BF00207247.
The negative symptoms of schizophrenia and the monoamine oxidase inhibitors.
Bucci L
Psychopharmacology (Berl). 1987; 91(1):104-8.
PMID: 3103152
DOI: 10.1007/BF00690936.
Effect of chlorpromazine on the localization of cAMP phosphodiesterase.
Seegers J, Haag M, van Heerden O, Joubert W, THERON J
Acta Neuropathol. 1985; 66(3):199-207.
PMID: 2990146
DOI: 10.1007/BF00688584.
Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo.
Zetterstrom T, Sharp T, Ungerstedt U
Naunyn Schmiedebergs Arch Pharmacol. 1986; 334(2):117-24.
PMID: 2946964
DOI: 10.1007/BF00505810.
Effects of fluperlapine on dopaminergic systems in rat brain.
Burki H
Psychopharmacology (Berl). 1986; 89(1):77-84.
PMID: 2942961
DOI: 10.1007/BF00175194.
Acute dystonia induced by neuroleptic drugs.
Rupniak N, Jenner P, Marsden C
Psychopharmacology (Berl). 1986; 88(4):403-19.
PMID: 2871578
DOI: 10.1007/BF00178501.
Do neuroleptic drugs still have a place in neurological therapy?.
Klockgether T, Dichgans J
J Neurol. 1990; 237(4):221-5.
PMID: 1975270
DOI: 10.1007/BF00314622.
Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.
Rivest R, Marsden C
Br J Pharmacol. 1991; 104(1):234-8.
PMID: 1786513
PMC: 1908259.
DOI: 10.1111/j.1476-5381.1991.tb12412.x.
Differential drug effects on dopamine concentrations and rates of turnover in the median eminence, olfactory tubercle and corpus striatum.
Gudelsky G, Moore E
J Neural Transm. 1976; 38(2):95-105.
PMID: 1271052
DOI: 10.1007/BF01262968.
Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.
Costall B, Naylor R
Psychopharmacologia. 1975; 43(1):69-74.
PMID: 1172258
DOI: 10.1007/BF00437617.
